Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis

Clinical Cancer Research

Volumn 13, Issue 17, 2007, Pages 5034-5040

  Signoroni, Stefano ^a   Frattini, Milo ^a,c   Negri, Tiziana ^a   Pastore, Elisa ^a   Tamborini, Elena ^a   Casieri, Paola ^a   Orsenigo, Marta ^a   Da Riva, Luca ^a   Radice, Paolo ^a,b   Sala, Paola ^a   Gronchi, Alessandro ^a   Bertario, Lucio ^a   Pierotti, Marco A ^a,b   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; CYCLOOXYGENASE 2 INHIBITOR; MESSENGER RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DESMOID TUMOR; FEMALE; FIBROMATOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DRUG ANTAGONISM; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; BETA CATENIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FIBROMATOSIS, AGGRESSIVE; GENES, APC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RNA, MESSENGER;

EID: 34548844748     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0336     Document Type: Article

References (22)

1. Penna C, Tiret E, Parc R, et al. Operation and abdominal desmoid tumors in familial adenomatous polyposis. Surg Gynecol Obstet 1993;177:263-8.
2. Giarola M, Wells D, Mondini P, et al. Mutations of a denomatous polyposis coli (APC) gene are uncommon in sporadic desmoid tumors. Br J Cancer 1998;78:582-7.
3. Tejpar S, Nollet F, Li C, et al. Predominance of β-catenin mutations and β-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18:6615-20.
4. Mendenhall WM, Zlotecki RA, Morris CG, et al. Aggressive fibromatosis. Am J Clin Oncol 2005;28:211-5.
5. Kundu JK, Choi KY, Surh YJ. β-Catenin-mediated signaling: a novel molecular target for chemoprevention with anti-inflammatory substances. Biochim Biophys Acta 2006;1765:14-24.
6. Dempke W, Rie C, Grothey A, et al. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001;127:411-7.
7. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24:1195-203.
8. Tamborini E, Negri T, Miselli F, et al. Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J Natl Cancer Inst 2006;98:1583-4.
9. Sunaga N, Kohno T, Kolligs FT, et al. Constitutive activation of the Wnt signaling pathway by CTNNB1 (β-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer 2001;30:316-21.
10. Frattini M, Balestra D, Suardi S, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004;10:4015-21.
11. Frattini M, Carnevali I, Signoroni S, et al. Cyclooxygenase-2 expression in FAP patients carrying germ line MYH mutations. Cancer Epidemiol Biomarkers Prev 2005;14:2049-52.
12. Lagonigro MS, Tamborini E, Negri T, et al. PDGFRα, PDGFRβ and KIT expression/activation in conventional chondrosarcoma. J Pathol 2006;208:615-23.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
14. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-90.
15. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000;18:1967-79.
16. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000;30:3-21.
17. Liegl B, Leithner A, Bauernhofer T, et al. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours? Histopatology 2006;49:576-81.
18. Poon R, Smits R, Li C, et al. Cyclooxygenase two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 2001;20:451-60.
19. Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006;24:102-5.
20. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007;97:247-74.
21. Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12:2622-7.
22. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006;33:407-20.